Head and Neck-Journal for the Sciences and Specialties of the Head and Neck最新文献

{"title":"Oncologic Outcomes and Treatment Feasibility of Transoral Carbon Dioxide Laser Microsurgery for Hypopharyngeal Tumors in Older Patients: A Retrospective Cohort Study.","authors":"Takeharu Ono, Shun-Ichi Chitose, Takashi Kurita, Fumihiko Sato, Mioko Fukahori, Shintaro Sueyoshi, Toshihiko Kawaguchi, Tunehiro Oka, Taikai Kuroiwa, Hirohito Umeno","doi":"10.1002/hed.70523","DOIUrl":"https://doi.org/10.1002/hed.70523","url":null,"abstract":"<p><strong>Background: </strong>We evaluated outcomes and complications of transoral CO₂ laser microsurgery (TLM) for hypopharyngeal tumors and its feasibility in ≥ 75-year-old patients.</p><p><strong>Methods: </strong>We retrospectively reviewed 116 patients (without metastases) treated from February 2012 to October 2024 at our hospital. Oncologic outcomes were analyzed using Kaplan-Meier curves (110 patients; median follow-up: 5.3 years).</p><p><strong>Results: </strong>Five-year local control, disease-specific survival, and overall survival rates were 87.8%, 94.6%, and 85.6%, respectively. Postoperative dysphagia, aspiration pneumonia, pharyngolaryngeal edema, and vocal fold paralysis occurred in 9%, 4%, 3%, and 3% of patients, respectively; none required tracheostomy or surgical hemostasis under general anesthesia. The group with a history of head and neck irradiation had higher rates of dysphagia (p = 0.010) and aspiration pneumonia (p = 0.031) than those without. Differences between age groups were nonsignificant.</p><p><strong>Conclusions: </strong>TLM appears safe and effective for older patients with appropriately selected hypopharyngeal tumors.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and Pathologic Response to Neoadjuvant Immunotherapy in Head and Neck Cancer: Preliminary Results From a Pilot Study.","authors":"Angeline A Truong, Laura Chen, Rex H Lee, Xin Wu, Hyunseok Kang, Ivan H El-Sayed, Jonathan R George, Chase M Heaton, Ilya Likhterov, Michael Chow, Mary Jue Xu, Patrick K Ha, Alain P Algazi, Katherine C Wai","doi":"10.1002/hed.70505","DOIUrl":"https://doi.org/10.1002/hed.70505","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate associations between obesity and pathologic response to neoadjuvant immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Methods: </strong>This was a retrospective cohort study conducted at a single tertiary academic center. We identified 42 patients with HNSCC treated with neoadjuvant ICI with or without chemotherapy. Obesity was defined as body mass index (BMI) ≥ 30 kg/m². The primary outcome was any pathologic response (partial, major, or complete response). Multivariable logistic regression was performed to assess associations between obesity and response, adjusting for smoking status and Eastern Cooperative Oncology Group (ECOG) performance status. BMI was also analyzed as a continuous variable. Adjusted predicted probabilities of response were estimated across BMI.</p><p><strong>Results: </strong>Seven patients (17%) were obese. Obese patients had lower rates of pathologic response compared to non-obese patients (29% vs. 69%). On multivariable analysis, obesity was associated with decreased odds of response (OR 0.10, 95% CI 0.02-0.72; p = 0.021). Increasing BMI was independently associated with lower odds of response, with a 15% decrease per 1 kg/m² increase [OR 0.85 (0.72-0.99), p = 0.039]. Adjusted predicted probability of response declined from ~85% at BMI 18 to 25% at BMI 40. In a subset of patients receiving immunotherapy alone, increasing BMI remained associated with decreased response [OR 0.66 (0.44-0.99), p = 0.045].</p><p><strong>Conclusion: </strong>In a small pilot cohort, obesity was associated with decreased pathologic response to neoadjuvant ICI in HNSCC. These findings contrast with the \"obesity paradox\" observed in recurrent/metastatic settings and suggest the relationship between metabolic state and immunotherapy response may be context-dependent. Further validation in larger cohorts is needed.</p><p><strong>Level of evidence: </strong>III.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism in Patients Hospitalized With Localized, Regional, and Metastatic Head and Neck Cancer.","authors":"Andrew G LoPolito, Ted Akhiwu, May Z Gao, Jason Semprini, Tammara L Watts, Trinitia Y Cannon, Nosayaba Osazuwa-Peters","doi":"10.1002/hed.70522","DOIUrl":"https://doi.org/10.1002/hed.70522","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) is a known complication in cancer patients, but data in head and neck cancer (HNC)-particularly distinguishing localized, regional, and metastatic disease-are limited.</p><p><strong>Methods: </strong>Using the 2016-2020 National Inpatient Sample, we examined adults ≥ 18 years with HNC, excluding patients with another primary malignancy. Metastatic status was categorized as localized, regional, and metastatic. Outcomes included odds of VTE, pulmonary embolism (PE), deep vein thrombosis (DVT), inhospital mortality, and prolonged length of stay (LOS ≥ 7 days). Multivariable logistic regression identified factors associated with these outcomes.</p><p><strong>Results: </strong>Among 62 032 unweighted (310 160 weighted) admissions, 75.0% had localized HNC, 12.7% had regional HNC, and 12.3% had metastatic HNC; 2.6% had VTE (2.4% localized HNC, 2.3% regional HNC, and 4.1% metastatic HNC). Compared with localized HNC, regional HNC was not associated with increased odds of VTE, PE, or DVT, whereas metastatic HNC was associated with higher adjusted odds of VTE (aOR 1.52; 95% CI: 1.30-1.78), PE (aOR 1.61; 95% CI: 1.32-1.98), and DVT (aOR 1.47; 95% CI: 1.18-1.83). VTE was associated with increased inhospital mortality (aOR 1.98; 95% CI: 1.64-2.40) and prolonged LOS (aOR 2.14; 95% CI: 1.92-2.39).</p><p><strong>Conclusion: </strong>In hospitalized patients, distant, but not regional, metastatic HNC is associated with higher odds of VTE, and VTE is associated with adverse in-hospital outcomes including increased mortality and prolonged LOS.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149231231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost Effectiveness Analysis of the Presto-Trial: A Three-Armed RCT Evaluating Prophylactic Swallowing Exercises in Head and Neck Cancer Patients During (Chemo)radio Treatment.","authors":"Alice Vergauwen, Leen Van den Steen, Margot Baudelet, Ann Goeleven, Sandra Nuyts, Daan Nevens, Hanne Massonet, Fréderic Duprez, Gwen Van Nuffelen","doi":"10.1002/hed.70515","DOIUrl":"https://doi.org/10.1002/hed.70515","url":null,"abstract":"<p><strong>Background: </strong>Research on oropharyngeal head and neck cancer (HNC) patients indicates that prophylactic swallowing exercises (PSE) during (C)RT can positively affect muscle strength, swallowing function and quality of life (QOL). Primary analyses of the PRESTO-trial showed higher adherence rates for PSE when exercising daily with a speech-language pathologist (SLP), compared to self-guided exercises with either an exercise diary or a digital application. Additionally, higher adherence rates were related to greater improvements in swallowing function and QOL. However, given limited healthcare resources, cost-effectiveness analyses are essential to inform the implementation of such rehabilitation strategies in dysphagia care. This secondary analysis of the PRESTO-data compares the costs and health effects of the three different service models: app-based, therapist-led (daily face-to-face, 20 sessions during (C)RT), and paper-led therapy.</p><p><strong>Methods: </strong>One hundred fifty patients receiving (chemo)radiotherapy (C)RT for oropharyngeal HNC were randomly assigned to one of the three exercise groups. All performing the same PSE protocol. The treatment protocol required daily training during the first 4 weeks of the (C)RT treatment program. Patients in the therapy group thereby received a total of 20 face-to-face therapy sessions. Health outcomes were expressed as utilities based on the EQ5D5L instrument measured at baseline, post (C)RT and 3 months post (C)RT. Costs were estimated from a health service perspective, including staff time, therapy resources and consumables. Incremental cost-effectiveness ratios (ICERs) were calculated as ΔCosts/ ΔQALYs.</p><p><strong>Results: </strong>No significant between-group differences were found for utilities. Only significant time effects were observed, with a significant decrease in utilities from baseline to post (C)RT and a significant increase from post (C)RT to 3 months post (C)RT. The therapist-led intervention was associated with the highest costs. The app-group intervention was dominated by the paper group in terms of cost-effectiveness as the utilities were comparable but at a higher cost in the app-group. Consequently, the ICER was computed between the paper-group and therapist-group and resulted in € 124 061,54/QALY.</p><p><strong>Conclusions: </strong>Despite the overall positive HR-QOL effects post 3 months, the daily therapist-led delivery of PSE therapy was not cost-effective relative to paper-based self-management. Under current resource constraints, low-cost delivery models represent the most economically efficient option. Future research should explore whether hybrid or targeted therapist involvement yields better value by preserving clinical benefit while reducing cost.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149231234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicoepidemiologic Profile of Oral Kaposi Sarcoma in People Living With HIV: A Systematic Review and Meta-Analysis.","authors":"Ericles Otávio, Rebeca Ferreira Badaró, Daniel Pignatari Mahet Rodrigues, Giselle de Medeiros Silva, José Alcides Almeida de Arruda, Victor Zanetti Drumond, Jefferson R Tenório, Lucas Alves Jural, Marcela Baraúna Magno, Lucianne Cople Maia, Bruno Augusto Benevenuto de Andrade","doi":"10.1002/hed.70520","DOIUrl":"https://doi.org/10.1002/hed.70520","url":null,"abstract":"<p><strong>Background: </strong>To characterize the clinicoepidemiologic profile of HIV-associated oral Kaposi sarcoma (OKS) and quantitatively synthesize its frequency, anatomical distribution, and temporal patterns across antiretroviral therapy (ART) eras.</p><p><strong>Methods: </strong>Six databases and gray literature were searched. Eligible observational, descriptive, and quasi-experimental studies were appraised using JBI tools. Random-effects meta-analyses of patient-based proportions and treatment-era subgroup were performed when compatible study-level denominators were available (PROSPERO: CRD420251105061).</p><p><strong>Results: </strong>Forty-eight studies comprising 1661 individuals were included, and 31 contributed to at least one meta-analysis. Pooled proportions were 0.85 (95% CI: 0.76-0.91) for palatal involvement and 0.44 (95% CI: 0.23-0.68) for OKS as a sentinel presentation of HIV. Pooled prevalence of OKS among people living with HIV was 0.06 (95% CI: 0.02-0.12). Compared with the pre-combination ART era, the combination ART era showed lower palatal (0.72 vs. 0.89; p = 0.0034) and gingival involvement (0.07 vs. 0.30; p = 0.0003), but more sentinel presentations (0.72 vs. 0.32; p = 0.0195). Methodological quality was moderate, with substantial heterogeneity.</p><p><strong>Conclusions: </strong>Pooled evidence confirms strong palatal predilection of HIV-associated OKS. Temporal subgroup findings suggest changes in oral distribution across ART eras while reinforcing its persistent role as a sentinel manifestation of HIV infection and persistent clinical relevance despite ART.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Endonasal Approach to the Medial Aspect of the Temporomandibular Joint Region.","authors":"Jun Wu, Weiwei Wang, Xiujuan Kou, Nyall R London, Lifeng Li","doi":"10.1002/hed.70521","DOIUrl":"https://doi.org/10.1002/hed.70521","url":null,"abstract":"<p><strong>Background: </strong>The temporomandibular joint (TMJ) region is the most superolateral aspect of exposure via an endonasal corridor, while studies regarding the endonasal approach to this specific region are lacking. This study aimed to provide a detailed step-by-step surgical technique to reveal the medial aspect of the TMJ region on cadaveric dissection, and to retrospectively review endonasal removal of tumors in this specific region.</p><p><strong>Methods: </strong>Cadaveric dissection was performed on 4 specimens to illustrate the surgical technique of endonasal access to the medial aspect of the TMJ region. Radiological measurement of distances from anterior nasal spine (D1), lateral pterygoid plate (D2), and foramen ovale (D3) to medial TMJ of bilateral sides on 100 continuous CT scans was performed. Five patients harbored tumors at the medial aspect of the TMJ region who underwent endonasal tumor removal were included in the study. The feasibility, perioperative morbidities, and clinical outcomes were assessed.</p><p><strong>Results: </strong>The contents at the medial aspect of TMJ region could be adequately exposed via an endonasal corridor on all 8 cadaveric sides. The average distances of D1, D2, and D3 were 88.20 ± 8.2 mm, 22.80 ± 3.4 mm, and 19.93 ± 1.73 mm, respectively. The pathologies were osteoblastoma (n = 2) and chemotherapeutic malignancies (one with osteosarcoma and two with rhabdomyosarcoma). Gross total resection was achieved in all five patients. A comprehensive treatment strategy was performed for 3 patients with malignancies. Postoperative trismus was encountered, while it gradually improved with minimal impact on quality of life. With an average follow up of 24.4 ± 9.84 months, no recurrence was detected.</p><p><strong>Conclusion: </strong>It is feasible to perform an endonasal approach to the medial aspect of the TMJ region. For select tumors, an endonasal approach can serve as a viable option for tumor removal with few complications in experienced hands.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Care Navigation Improves Timeliness of Treatment in Head and Neck Cancer.","authors":"Atif M Islam, Robert B Baldwin, Alec E Dallas, Brandon J Dyer, Alisa Vidwans, Emma Dunn, Chantell Preziosi, Samer T Elsamna, Julia Toman, Tara Mokhtari, Christopher J Nickel, Matthew Mifsud","doi":"10.1002/hed.70513","DOIUrl":"https://doi.org/10.1002/hed.70513","url":null,"abstract":"<p><strong>Background: </strong>Timely access to oncologic care is critical for patients with head and neck cancer (HNC), yet delays in treatment remain widespread. We sought to determine whether implementation of a care navigation program was associated with improved timeliness.</p><p><strong>Methods: </strong>Four hunded and four adult patients who underwent HNC resection with free flap reconstruction were retrospectively reviewed. The primary outcome was time to adjuvant therapy and disease-free survival.</p><p><strong>Results: </strong>Median [IQR] age was 64 [58-73] years and 133 (33%) were women. Significant interval decreases were observed from surgery to initiation of adjuvant radiotherapy (56 [39-83] vs. 45 [31-64] days, p = 0.004). Log-rank testing revealed no difference in disease-free survival between pre- and postprogram cohorts (p = 0.7695).</p><p><strong>Conclusions: </strong>Implementation of a care navigation program was associated with significant reductions in time to treatment. These findings suggest that structured pathways can meaningfully improve oncologic care delivery for HNC patients.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous Leiomyosarcoma of the Head and Neck: Appreciation of a More Indolent Biological Behavior and Implications for Its Management.","authors":"Eelco de Bree, Remco de Bree, Carlos Chiesa-Estomba, Orlando Guntinas-Lichius, M P Sreeram, Dimosthenis Michelakis, Karthik N Rao, Alessandra Rinaldo, Alfio Ferlito","doi":"10.1002/hed.70512","DOIUrl":"https://doi.org/10.1002/hed.70512","url":null,"abstract":"<p><strong>Background: </strong>Leiomysosarcoma (LMS) is generally associated with high metastatic potential and poor survival. Cutaneous LMS (cLMS) has been considered a different entity with more indolent biological behavior.</p><p><strong>Methods: </strong>A narrative review was performed to assess the biological behavior of cLMS, with special attention for the head and neck location.</p><p><strong>Results: </strong>cLMS is located in the head and neck in 21%-33%. The local recurrence rate is 2%-18%, while only 3% develops metastatic disease at 10 years. The most important risk factor of recurrent disease is positive/close surgical margins, with a trend for increased risk at the head and neck. The vast majority of recurrences are local and appear during the first few years. No data support adjuvant treatment. The 5-year disease-specific survival is 96%-100%.</p><p><strong>Conclusions: </strong>cLMS exhibits a moderate risk of local recurrence, low metastatic potential, and excellent disease-specific survival. Surveillance may be focused on physical examination and limited in duration.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic Body Radiation Therapy for Management of Locally Advanced Periorbital Tumors: Efficacy and Toxicity Profile.","authors":"Oluwatimileyin Ojo, Kamaldeep Gill, Breanna Huang, Bin Gui, Jeff Antone, Shaheer Khan, Craig Devoe, Nagashree Seetharamu, Maged Ghaly","doi":"10.1002/hed.70508","DOIUrl":"https://doi.org/10.1002/hed.70508","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The management of locally advanced periorbital skin tumors with orbital invasion is challenging. Orbital exenteration historically provides reliable local control but causes major functional and cosmetic morbidity. We evaluated stereotactic body radiation therapy (SBRT) as an eye-sparing alternative, focusing on local control, vision preservation, and toxicity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective series includes 26 consecutive patients with locally advanced periorbital tumors treated prospectively with SBRT. Tumors involved the canthi (zones III-IV) in 20 patients, with multi-zone involvement in 18 and complete periorbital skin invasion (zone V) in 4. Eighteen tumors violated the orbital septum; anterior orbital invasion was observed in 16, and middle orbital invasion in 14. Extraconal violation occurred in 16 patients, and intraconal invasion in 15 patients. All patients were presented with intact ipsilateral vision at baseline. SBRT was delivered using VMAT/IMRT with a simultaneous integrated boost of 35-40 Gy to GTV and 25 Gy to CTV + 2 mm over five biweekly fractions. Optic apparatus constraints included Orbit PRV and Optic N PRV maximum point ≤ 30 Gy and mean ≤ 20 Gy; Lacrimal gland mean &lt; 26 Gy when feasible. OAR constraints were based on institutional treatment directives supported by AAPM TG-101, QUANTEC, and Emami et al. 50% received systemic therapy, including immunotherapy, targeted therapy, or chemotherapy, with some receiving combined approaches. Local and regional control and toxicities (CTCAE v5.0) were recorded; statistical analysis was primarily descriptive. Kaplan-Meier methodology was used to estimate local control and overall survival. Given the limited cohort size and heterogeneous tumor histologies, no formal comparative statistical testing was performed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Twenty-four patients presented with primary cutaneous tumors and 2 had non-cutaneous histologies (solitary fibrous tumor and metastatic breast carcinoma). SBRT was delivered as definitive therapy in 19 patients and as adjuvant therapy in 7. Median planning target volumes (PTVs) were 45 cc (PTV25) and 9 cc (PTV35-40 Gy), with corresponding median D90 values of 29 and 34/42 Gy, respectively. At a median follow-up of 18 months (range 4-50 months), all patients retained intact vision. Twenty-one patients achieved complete response, one had stable disease, and three experienced locoregional recurrences-one cavernous sinus failure and two local-regional relapses. Acute toxicities were predominantly mild, including Grade 1 dermatitis (n = 15), conjunctivitis (n = 8), diplopia (n = 7), orbital pain (n = 1), and hyperpigmentation (n = 2). Grade 2 dermatitis occurred in 6 patients, while Grade 3 dermatitis was rare (n = 2), both requiring reconstructive grafting. On follow-up, late effects included blurred vision (n = 6), epiphora (n = 3), orbital pain (n = 2), and cataract progression (n = 2), with isolat","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glypican-1-Targeted Antibody-Drug Conjugate Exhibits Antitumor Effects Against Oral Squamous Cell Carcinoma.","authors":"Kengo Obata, Satoshi Serada, Yuji Suzuki, Kodai Tuchida, Jun Miyaguchi, Eiji Funajima, Hiroyuki Yamada, Tetsuji Naka","doi":"10.1002/hed.70514","DOIUrl":"https://doi.org/10.1002/hed.70514","url":null,"abstract":"<p><strong>Background: </strong>Oral squamous cell carcinoma (OSCC) is a major health concern with limited therapeutic options. Glypican-1 (GPC1), a heparan sulphate proteoglycan, has been implicated in several malignancies; however, its therapeutic role in OSCC remains elusive. This study investigated the potential of a novel glypican-1 antibody-drug conjugate (GPC1-ADC) conjugated with monomethyl auristatin E as a therapeutic strategy for OSCC.</p><p><strong>Methods: </strong>GPC1 expression in OSCC tissues was examined by immunohistochemistry using tissue microarrays and by western blotting in OSCC cell lines. The cytotoxicity of GPC1-ADC was assessed using in vitro viability assays, and its effects on the cell cycle and apoptosis were analyzed using flow cytometry and caspase-3/7 activity assays. In vivo antitumor efficacy was evaluated using OSCC cell line-derived and patient-derived xenograft (PDX) mouse models.</p><p><strong>Results: </strong>High GPC1 expression was observed in 78% (39/50) of OSCC cases, whereas normal oral tissues showed no detectable expression. Western blotting confirmed GPC1 protein expression in all the OSCC cell lines tested. GPC1-ADC markedly reduced cell viability in a dose-dependent manner (IC5₅₀ = 0.053-0.117 nM), induced G2/M-phase arrest, and activated caspase-3/7, indicating apoptosis. In vivo, high-dose GPC1-ADC markedly inhibited tumor growth in both xenograft and PDX models compared with control treatments, without causing weight loss.</p><p><strong>Conclusion: </strong>GPC1-ADC demonstrated potent and specific antitumor activity against GPC1-expressing OSCC in vitro and in vivo. These findings suggest that GPC1-ADC is a promising therapeutic candidate for OSCC and may provide a basis for new treatment strategies; however, further preclinical and clinical evaluation is warranted.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}